Mineralys Therapeutics, Inc. - MLYS

SEC Filings Our MLYS Tweets

About Gravity Analytica

Recent News

10.28.2026 - Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
10.28.2026 - Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
10.22.2026 - Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
10.22.2026 - ASN 2026: Blood Pressure and Albuminuria Reduction with Lorundrostat in CKD Stages 1 to 3 in the Launch-HTN trial
10.19.2026 - Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
10.09.2026 - Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
10.09.2026 - AHA Hypertension 2026: Efficacy and Safety of the Selective Aldosterone Synthase Inhibitor Lorundrostat in Moderate-to-Severe Apnea and Hypertension: Explore-OSA Randomized Crossover Trial
10.09.2026 - AHA Hypertension 2026: Blood Pressure Responder Analysis in the Global Launch-HTN Trial of Lorundrostat in Uncontrolled and Resistant Hypertension
10.09.2026 - AHA Hypertension 2026: Lorundrostat Mitigates Cardiorenal Injury Independent of Blood Pressure Reduction in an L-NAME/Angiotensin II Rat Model
10.09.2026 - AHA Hypertension 2026: Real-world Utilization and Treatment Patterns of Spironolactone in Patients with Hypertension

Recent Filings